The American Epilepsy Society's (AES) 72nd Annual Meeting convened on November 30 to December 4, 2018. At the meeting, AES promotes both basic and clinical research at the vanguard of diagnosing, treating, and curing epilepsy offering high-quality educational content across diverse work settings, professional roles, and experience levels.
The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.
The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.
The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.
The neurologist and epileptologist at the Mayo Clinic in Jacksonville spoke about how to best identify adult patients in need of routine EEG and what it will bring to the table relative to the clinician.
The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.
The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the long-term seizure freedom data that showed that perampanel was associated with a sustained or increased improvement in seizure control.
The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.
The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.
The SVP and chief strategy and development officer at Aquestive Therapeutics discussed the hope to provide both patients and providers with a more favorable, and still efficacious, option for seizure clusters.
The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.